Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Europe and ROW focus - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Pharma: Europe and ROW focus

Jul 17, 2007

The high level of competition witnessed in the US generics market has propelled generic companies both in India and globally to geographically diversify in a bid to de-risk their revenue profile and sustain overall profitability. And while Europe has been the next best choice, the emerging markets of Latin America, Africa, CIS and central and Eastern Europe have also come on the radar of domestic pharma companies. In this article, we shall take a look at the potential of these markets and the challenges going forward. Why Europe?

Europe is a heterogeneous market as compared to the US with each country having different market characteristics and regulations. Besides this, while the generics penetration in the UK and Germany is high, the same is relatively lesser in markets such as France, Italy and Spain, indicating the potential for generics to gain traction going forward. Akin to the US, the governments of the European nations are also under pressure to reduce healthcare costs given the rise in the aged population and thereby the increased spending on pharmaceuticals. Also, branded generics can be launched in some of these markets, as a result of which companies here can earn higher profits. Thus, domestic pharma companies having been making increasing strides in the European markets by acquiring companies with a strong product pipeline and an established marketing network. The rationale for making acquisitions is to obviate the need to establish a presence in Europe right from scratch.

Why the emerging markets?

Domestic pharma companies have evinced a lot of interest in the emerging markets of late as these markets have been growing much faster than the US and Europe, posting double-digit growth rates. Since these markets are not as regulated as those in the US and Europe, generics here can be branded, consequently enabling companies to earn higher margins. The disease profile in these countries is also shifting towards the chronic therapy segment and in the African continent, organisations such as the WHO and the PEPFAR are playing an important role in funding healthcare costs (especially for diseases such as AIDS, the prevalence of which is very high in Africa). Hence, given the potential, domestic pharma companies are setting shop in these countries to boost revenues and profitability and partially offset the pricing pressure witnessed not only in the US market but also in some of the western European countries.

The challenges are...

While Europe is increasingly becoming a focus area for domestic pharma companies, there has been a perceptible shift in the dynamics of the western European markets. For instance, the UK has been facing severe pricing pressure and regulatory changes in France and Germany have taken its toll on the performance of Indian companies present in these markets. To put things into perspective, while Germany initially was a branded generics market, the new set of regulatory changes in the German healthcare system are expected to commoditise generics going forward. This means that pricing pressure is likely to be persistent in this market as well. While the efforts of the government to increase the use of generics will bolster volumes, efforts to control costs is likely to escalate into pricing pressure going forward.

In the emerging markets, competition is likely to intensify as more and more companies establish a presence in these countries. Despite this, the growth in revenues and margins are likely to be on the higher side as compared to the US and Western Europe. This is because these emerging markets have been growing at a much faster pace led by a higher per capita pharmaceutical expenditure and an increasing utilisation of generic drugs.

To sum up...

Presence across geographies has been gaining momentum across global generic companies. Besides domestic companies such as Ranbaxy, Dr.Reddy's and Sun Pharma, global generic companies such as Teva and Mylan have also been focusing on establishing a global footprint and hence have been active on the acquisition front. Given the high barriers to entry in terms of product introduction and a strong marketing network, at the end of the day those pharma companies, which have a wider geographical reach, will have the upper edge over their peers in the longer term.

Equitymaster requests your view! Post a comment on "Pharma: Europe and ROW focus". Click here!


More Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Apr 18, 2019 (Close)